DE3940389A1 - Therapeutical compsn. comprising gas, e.g. oxygen dissolved in liq. - for immuno-stimulation in cancer therapy, reviving accident victims and improving oxygen transport in vascular coronary diseases - Google Patents

Therapeutical compsn. comprising gas, e.g. oxygen dissolved in liq. - for immuno-stimulation in cancer therapy, reviving accident victims and improving oxygen transport in vascular coronary diseases

Info

Publication number
DE3940389A1
DE3940389A1 DE3940389A DE3940389A DE3940389A1 DE 3940389 A1 DE3940389 A1 DE 3940389A1 DE 3940389 A DE3940389 A DE 3940389A DE 3940389 A DE3940389 A DE 3940389A DE 3940389 A1 DE3940389 A1 DE 3940389A1
Authority
DE
Germany
Prior art keywords
gas
oxygen
compsn
liq
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE3940389A
Other languages
German (de)
Inventor
Abolghassem Prof Dr M Pakdaman
Hans-Joachim Dipl Ing Weickert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WEICKERT HANS JOACHIM DIPL ING
Original Assignee
WEICKERT HANS JOACHIM DIPL ING
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WEICKERT HANS JOACHIM DIPL ING filed Critical WEICKERT HANS JOACHIM DIPL ING
Priority to DE3940389A priority Critical patent/DE3940389A1/en
Publication of DE3940389A1 publication Critical patent/DE3940389A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/08—Mineral waters; Sea water
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/54—Mixing with gases
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compsn. comprises a liq. contg. physiologically acceptable gas, the gas in an amt. higher than the normal gas satn. level. The gas is esp. oxygen, ozone or a noble gas. The liq. esp. drinking water. The gas in concns. of at least 20 mg/l. Compsns. are claimed contg. oxygen at a concn. of at least 40 mg/l, pref. 50 mg/l or more. The compsn. may also contain trace amts. of selenium and/or germanium. USE/ADVANTAGE - Useful as an immunostimulator in cancer treatment. In this case administration is oral, intraveneous or rectal and gives increased blood oxygen levels. It may also be used in shock treatment and/or as an oxygen carrier and blood substitute for reviving accident victims. The compsn. may also be useful for wound cleaning or tumour infiltration and for improving oxygen transport in coronary vascular diseases and lung conditionoun

Description

Die Erfindung betrifft ein therapeutisches Mittel, das aus einer Flüssigkeit besteht, die ein Gas enthält.The invention relates to a therapeutic agent consisting of a Liquid consists of a gas.

Es ist bekannt, daß bestimmte Gase wie Sauerstoff und Ozon, besonders bei Krebspatienten, immunstimulierend wirken. Bisher ist es jedoch nicht gelungen, dem menschlichen Körper derartige Gase in einfacher und wirkungsvoller Weise in ausreichender Menge zuzuführen.It is known that certain gases, such as oxygen and ozone, especially in Cancer patients, have an immunostimulating effect. So far, however, it is not succeeded in making such gases easier and easier for the human body effective supply in sufficient quantities.

Der Erfindung liegt die Aufgabe zugrunde, ein therapeutisches Mittel zu schaffen, mit dessen Hilfe dem menschlichen Körper Gase wie Sauerstoff in ausreichender Menge ohne Nebenwirkungen zugeführt werden können.The object of the invention is to provide a therapeutic agent create, with the help of the human body gases like oxygen in sufficient amount can be fed without side effects.

Diese Aufgabe wird erfindungsgemäß mit einem therapeutischen Mittel gelöst, das eine physiologisch körperverträgliche Flüssigkeit aufweist, die mit dem zuzuführenden Gas in einer über dem natürlichen Gas- Sättigungsgrad der Flüssigkeit liegenden Konzentration angereichert ist.This object is achieved with a therapeutic agent dissolved, which has a physiologically tolerable fluid, with the gas to be supplied in a above natural gas Degree of saturation of the liquid lying concentration is enriched.

Vorzugsweise ist das Gas, mit welchem die Flüssigkeit angereichert ist, Sauerstoff, aber auch Ozon oder ein Edelgas. Als Flüssigkeit kann zweckmäßig übliches Trinkwasser verwendet werden, das mit Sauerstoff angereichert ist.The gas with which the liquid is enriched is preferably Oxygen, but also ozone or an inert gas. As a liquid can Appropriate common drinking water can be used with oxygen is enriched.

Die Gaskonzentration in der Flüssigkeit beträgt zweckmäßig bei normalem Druck und Raumtemperatur wenigstens etwa 20 mg/l und vorzugsweise etwa 40 oder sogar 50 mg/l und höher.The gas concentration in the liquid is appropriately normal Pressure and room temperature at least about 20 mg / l and preferably about 40 or even 50 mg / l and higher.

Durch die Erfindung wird ein therapeutisches Mittel geschaffen, welches das Blutbild und auch das Immunsystem, besonders bei Krebspatienten, deutlich verbessert und stimuliert. The invention provides a therapeutic agent which the blood picture and also the immune system, especially in cancer patients, significantly improved and stimulated.  

Die Verbesserung des Blutbildes und Stimulierung des Immunsystems erfolgt bei intravenöser, oraler und auch rektaler Anwendung durch erhöhte Sauerstoffzufuhr zum Blut und durch Resorption über die Magen- und Darmpassage.The improvement of the blood picture and stimulation of the immune system takes place with intravenous, oral and also rectal use by increased Oxygenation to the blood and through absorption through the stomach and Intestinal passage.

Es ist aber auch möglich, das erfindungsgemäße therapeutische Mittel, beispielsweise für Zwecke der Katastrophenmedizin und der Schockbekämpfung, einzusetzen und dem Patienten durch Infusion als Blutersatzmittel und als Sauerstofftransporter zu verabreichen, beispielsweise um Unfallopfer schnell zu beleben.However, it is also possible to use the therapeutic agent according to the invention, for example for the purposes of disaster medicine and Combating shock, use and the patient by infusion as To administer blood substitutes and as an oxygen transporter, for example, to quickly revive accident victims.

Schließlich ist es auch möglich, das erfindungsgemäße therapeutische Mittel für Wundspülung oder für Tumor-Infiltration zu verwenden.Finally, it is also possible to use the therapeutic Use agent for wound irrigation or for tumor infiltration.

Ein wesentlicher Aspekt der vorliegenden Erfindung ist, daß mit dem erfindungsgemäßen therapeutischen Mittel in einfachster Weise dem menschlichen Körper Sauerstoff oder ein anderes Gas, beispielsweise Ozon oder ein Edelgas, in größeren Mengen zugeführt wird.An essential aspect of the present invention is that with the Therapeutic agents according to the invention in the simplest way human body oxygen or another gas such as ozone or an inert gas, is supplied in larger quantities.

Es ist bekannt, daß Sauerstoff das als Krebs bezeichnete unkontrollierte Wachstum von Zellen bremst oder gar unterdrückt. Daher kann man mit dem erfindungsgemäßen therapeutischen Mittel Krebskrankheiten wirksam bekämpfen.Oxygen is known to be the uncontrolled one called cancer Cell growth slows down or even suppresses. Therefore you can with the therapeutic agents according to the invention effective cancer diseases fight.

Durch kombinierte perorale bzw. Infusions-Sauerstoff-Therapie mit Hyperthermie kann eine Schädigung der Krebszelle sowie eine Stimulierung des Immunsystems erreicht werden.Through combined oral or infusion oxygen therapy with Hyperthermia can damage the cancer cell as well as stimulate it of the immune system.

Der Sauerstoffgehalt von normalem Trinkwasser liegt zwischen 5 und 9,5 mg/l und beträgt vorzugsweise etwa 7 mg/l. Ein derartiger Sauerstoffgehalt reicht aber für den zur Behandlung aller Arten von zellulärem Sauerstoffmangel, besonders bei Krebs-, Herzgefäß- und Lungenkrankheiten, benötigten Sauerstofftransport in den Körper nicht aus. Die Erfindung sieht daher vor, einen wesentlich höheren Gas- und insbesondere Sauerstoffanteil im Wasser, das physiologisch körperverträglich ist, zu erreichen, um einen erhöhten Sauerstofftransport zu verschiedenen Körperbereichen mit positivem Therapieeffekt zu erzielen. The oxygen content of normal drinking water is between 5 and 9.5 mg / l and is preferably about 7 mg / l. Such an oxygen content but is enough for the treatment of all types of cellular Lack of oxygen, especially cancer, cardiovascular and lung diseases, do not require oxygen transport into the body. The invention therefore provides for a much higher gas and in particular Percentage of oxygen in water that is physiologically compatible with the body achieve increased oxygen transport to different To achieve areas of the body with a positive therapeutic effect.  

Während der Sättigungsgrad von gelöstem atmosphärischen Sauerstoff in Wasser bei 16°C bei etwa 9,95 mg/l liegt, weist beispielsweise eine erfindungsgemäße isotonische Kochsalzlösung bei 16 °C einen Anteil von mindestens 24 mg/l und bis 40 mg/l Sauerstoff auf.During the degree of saturation of dissolved atmospheric oxygen in Water at 16 ° C is about 9.95 mg / l, for example isotonic saline solution according to the invention at 16 ° C. at least 24 mg / l and up to 40 mg / l oxygen.

Auch destilliertes Wasser ist als Flüssigkeit für das erfindungsgemäße therapeutische Mittel geeignet. Eine Untersuchung mit destilliertem Wasser ergab, daß dieses Wasser bei 20°C vor der Sauerstoffanreicherung einen Sauerstoffgehalt von 11,2 mg/l und nach der Sauerstoffanreicherung einen Sauerstoffgehalt von 42,5 mg/l aufwies.Distilled water is also a liquid for the invention therapeutic agents. An examination with distilled water found that this water at 20 ° C before oxygenation Oxygen content of 11.2 mg / l and one after oxygen enrichment It had an oxygen content of 42.5 mg / l.

Nach einem weiteren Merkmal der Erfindung können der Flüssigkeit des therapeutischen Mittels beispielsweise Spurenelemente und/oder Mineralien zugegeben werden. Die therapeutische Wirksamkeit des Mittels wird dadurch weiter verbessert.According to a further feature of the invention, the liquid of the therapeutic agents, for example trace elements and / or minerals be added. The therapeutic effectiveness of the agent is thereby further improved.

Als Spurenelemente sind Selen und Germanium bevorzugt.Selenium and germanium are preferred as trace elements.

Claims (7)

1. Therapeutisches Mittel bestehend aus einer Gas enthaltenden Flüssigkeit dadurch gekennzeichnet, daß die Flüssigkeit physiologisch körperverträglich und mit dem Gas in einer über deren natürlichem Gas-Sättigungsgrad liegenden Konzentration angereichert ist.1. Therapeutic agent consisting of a gas-containing liquid, characterized in that the liquid is physiologically compatible with the body and enriched with the gas in a concentration above their natural gas saturation level. 2. Mittel nach Anspruch 1, dadurch gekennzeichnet, daß das Gas Luftsauerstoff, Ozon oder ein Edelgas ist.2. Composition according to claim 1, characterized in that the gas Atmospheric oxygen, ozone or an inert gas. 3. Mittel nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß die Flüssigkeit übliches Trinkwasser und das Gas Luftsauerstoff ist.3. Means according to claim 1 or 2, characterized in that the Liquid is common drinking water and the gas is atmospheric oxygen. 4. Mittel nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß das Gas in einer Konzentration von wenigstens etwa 20 mg/l bei normalem Druck und bei Raumtemperatur in der Flüssigkeit enthalten ist.4. Agent according to one of claims 1 to 3, characterized in that the gas at a concentration of at least about 20 mg / l normal pressure and at room temperature in the liquid is. 5. Mittel nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, daß die Flüssigkeit übliches Trinkwasser ist und Sauerstoff in einer Konzentration von wenigstens etwa 40 mg/l und vorzugsweise von etwa 50 mg/l und mehr enthält.5. Agent according to one of claims 1 to 4, characterized in that the liquid is common drinking water and oxygen in one Concentration of at least about 40 mg / l, and preferably about Contains 50 mg / l and more. 6. Mittel nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß die Flüssigkeit ihr zugegebene Spurenelemente und Mineralien enthält.6. Agent according to one of claims 1 to 5, characterized in that the liquid contains added trace elements and minerals. 7. Mittel nach Anspruch 6, dadurch gekennzeichnet, daß die Flüssigkeit als Spurenelemente Selen und/oder Germanium enthält.7. Composition according to claim 6, characterized in that the liquid contains selenium and / or germanium as trace elements.
DE3940389A 1989-12-06 1989-12-06 Therapeutical compsn. comprising gas, e.g. oxygen dissolved in liq. - for immuno-stimulation in cancer therapy, reviving accident victims and improving oxygen transport in vascular coronary diseases Withdrawn DE3940389A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE3940389A DE3940389A1 (en) 1989-12-06 1989-12-06 Therapeutical compsn. comprising gas, e.g. oxygen dissolved in liq. - for immuno-stimulation in cancer therapy, reviving accident victims and improving oxygen transport in vascular coronary diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3940389A DE3940389A1 (en) 1989-12-06 1989-12-06 Therapeutical compsn. comprising gas, e.g. oxygen dissolved in liq. - for immuno-stimulation in cancer therapy, reviving accident victims and improving oxygen transport in vascular coronary diseases

Publications (1)

Publication Number Publication Date
DE3940389A1 true DE3940389A1 (en) 1991-06-13

Family

ID=6394947

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3940389A Withdrawn DE3940389A1 (en) 1989-12-06 1989-12-06 Therapeutical compsn. comprising gas, e.g. oxygen dissolved in liq. - for immuno-stimulation in cancer therapy, reviving accident victims and improving oxygen transport in vascular coronary diseases

Country Status (1)

Country Link
DE (1) DE3940389A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0596621A1 (en) * 1992-11-06 1994-05-11 Bernard Frederick Schroeder Method of production of a beverage for human consumption
WO1996025057A1 (en) * 1995-02-13 1996-08-22 Dariush Behnam Non-alcoholic drink, the use thereof and a process for producing the drink
DE29715191U1 (en) * 1997-08-23 1998-02-05 Heydarpour-Ghazvini, Esmaeil, Dr., 37081 Göttingen Drinking water that is enriched with oxygen
WO1998024456A1 (en) * 1996-12-03 1998-06-11 Lisa Marlene Jeffreys Smith Reactive oxygen intermediates containing compounds effective in inducing cell differentiation of malignant cells such as leukemia
EP0847959A1 (en) * 1996-11-19 1998-06-17 KS & P Industrietechnik GmbH Method for preparing and filling of oxygen-enriched or oxygen containing gas enriched liquids and beverage prepared by such a method
EP0864329A1 (en) * 1997-03-10 1998-09-16 Michael Dr. Georgieff Medical preparations containing a lipophile noble gas
EP0900761A1 (en) * 1997-09-04 1999-03-10 Kramer & Co. OEG Method for preparing and filling of oxygen-enriched or oxygen containing gas enriched liquids and beverage prepared by such a method
ES2133083A1 (en) * 1996-11-21 1999-08-16 Garcia Lorenzo Vicente Combined formula for eliminating chronic ischaemia in extremities.
WO2000010576A1 (en) * 1998-08-20 2000-03-02 Polygon Health Care Gmbh Method of producing means for treating the human body
DE19818631C2 (en) * 1997-04-29 2000-05-25 Wilhelm Kohne Fa Method and device for enriching a liquid with a gas
DE10037529A1 (en) * 2000-08-01 2002-02-21 Michael H Schoenberg Oxygenated agent and its use for therapeutic purposes
WO2003077933A1 (en) * 2002-03-20 2003-09-25 London Health Sciences Centre Research Inc. Increasing tumor oxygen content by administration of stressed cells
DE10201825A1 (en) * 2002-01-18 2003-11-27 Oxywell Gmbh & Co Sauerstoffte Use of oxygenated water
WO2005097236A1 (en) * 2004-04-07 2005-10-20 Philipps-Universität Marburg Device for the intraperitoneal application of a fluid comprising ozone or ozonised oxygen, in a human or animal body and use thereof

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0596621A1 (en) * 1992-11-06 1994-05-11 Bernard Frederick Schroeder Method of production of a beverage for human consumption
WO1996025057A1 (en) * 1995-02-13 1996-08-22 Dariush Behnam Non-alcoholic drink, the use thereof and a process for producing the drink
EP0847959A1 (en) * 1996-11-19 1998-06-17 KS & P Industrietechnik GmbH Method for preparing and filling of oxygen-enriched or oxygen containing gas enriched liquids and beverage prepared by such a method
ES2133083A1 (en) * 1996-11-21 1999-08-16 Garcia Lorenzo Vicente Combined formula for eliminating chronic ischaemia in extremities.
US6399664B2 (en) 1996-12-03 2002-06-04 Lisa Marlene Jefferys Smith Method of treating cancer, specifically leukemia, with ozone
WO1998024456A1 (en) * 1996-12-03 1998-06-11 Lisa Marlene Jeffreys Smith Reactive oxygen intermediates containing compounds effective in inducing cell differentiation of malignant cells such as leukemia
DE19709704C2 (en) * 1997-03-10 1999-11-04 Michael Georgieff Use of a liquid preparation of xenon for intravenous administration when inducing and / or maintaining anesthesia
US6197323B1 (en) 1997-03-10 2001-03-06 Michael Georgieff Medicinal preparation containing a lipophilic inert gas
WO1998040083A1 (en) * 1997-03-10 1998-09-17 Michael Georgieff Medicinal preparation containing a lipophilic inert gas
DE19709704A1 (en) * 1997-03-10 1998-09-24 Michael Prof Dr Georgieff Preparation containing dissolved or dispersed a gas with a pharmacological effect
AP1162A (en) * 1997-03-10 2003-06-30 Michael Georgieff Medical preparation containing a lipophilic inert gas.
EP0864328A1 (en) * 1997-03-10 1998-09-16 Michael Dr. Georgieff Apparatus for controlled anaesthesia, analgesia and/or sedation
EP0864329A1 (en) * 1997-03-10 1998-09-16 Michael Dr. Georgieff Medical preparations containing a lipophile noble gas
US6511453B2 (en) 1997-03-10 2003-01-28 Michael Georgieff Device for controlled anaesthesia, analgesia and/or sedation
AU738946C (en) * 1997-03-10 2002-05-02 Michael Georgieff Medicinal preparation containing a lipophilic inert gas
WO1998040084A1 (en) * 1997-03-10 1998-09-17 Michael Georgieff Device for controlled anaesthesia, analgesia and/or sedation
AU738946B2 (en) * 1997-03-10 2001-09-27 Michael Georgieff Medicinal preparation containing a lipophilic inert gas
DE19818631C2 (en) * 1997-04-29 2000-05-25 Wilhelm Kohne Fa Method and device for enriching a liquid with a gas
DE29715191U1 (en) * 1997-08-23 1998-02-05 Heydarpour-Ghazvini, Esmaeil, Dr., 37081 Göttingen Drinking water that is enriched with oxygen
EP0900761A1 (en) * 1997-09-04 1999-03-10 Kramer & Co. OEG Method for preparing and filling of oxygen-enriched or oxygen containing gas enriched liquids and beverage prepared by such a method
WO2000010576A1 (en) * 1998-08-20 2000-03-02 Polygon Health Care Gmbh Method of producing means for treating the human body
DE10037529A1 (en) * 2000-08-01 2002-02-21 Michael H Schoenberg Oxygenated agent and its use for therapeutic purposes
DE10201825A1 (en) * 2002-01-18 2003-11-27 Oxywell Gmbh & Co Sauerstoffte Use of oxygenated water
WO2003077933A1 (en) * 2002-03-20 2003-09-25 London Health Sciences Centre Research Inc. Increasing tumor oxygen content by administration of stressed cells
WO2005097236A1 (en) * 2004-04-07 2005-10-20 Philipps-Universität Marburg Device for the intraperitoneal application of a fluid comprising ozone or ozonised oxygen, in a human or animal body and use thereof

Similar Documents

Publication Publication Date Title
DE60103453T2 (en) Use of albumin stabilized paclitaxel for the manufacture of a medicament for treating solid tumors and the drug so obtained
DE3940389A1 (en) Therapeutical compsn. comprising gas, e.g. oxygen dissolved in liq. - for immuno-stimulation in cancer therapy, reviving accident victims and improving oxygen transport in vascular coronary diseases
DE69930375T2 (en) XYLITOL COMPOSITIONS FOR THE TREATMENT OF THE UPPER BREATHING SYSTEMS
DE69404675T2 (en) PHARMACEUTICAL COMPOSITION FOR INTRANASAL ADMINISTRATION OF HYDROXOCOBALAMINE
EP0200155B1 (en) Aqueous solution of a chlorite matrix
DE1902227A1 (en) Medicines for psychotherapeutic use and processes for their manufacture
DE3048211A1 (en) SODIUM NITROPRUSSIDE SODIUM THIOSULFATE PERFUSOR KIT
DE194851T1 (en) THERAPY OF HUMAN TUMORS.
Cunningham Oxygen Therapy by Means of Compressed Air.
DE3602370A1 (en) Use of analgesics by inhalation
DE60000325T2 (en) Therapeutic use of a helium / oxygen mixture, especially for the treatment of asthma
DE60124516T3 (en) COMBINATION OF THE LEZITHINE WITH ASCORBIC ACID
EP2581082B1 (en) Pharmaceutical composition for treating status asthmaticus
EP1019037B9 (en) Medicament containing delta-aminolevulinic acid
DE2820899C2 (en)
DE4100782C2 (en)
DE19837790A1 (en) Manufacture of human pharmaceuticals, foodstuffs and cosmetics comprises the use of one or more physiologically compatible gases to enrich and potentiate the activity of the basic ingredients
DE3334751C2 (en)
DE10238161A1 (en) Mucosal or topical administration of minerals, e.g. for treating muscle spasms, psoriasis or osteoporosis or promoting wound healing, comprises direct application of mineral solution from ampoule
DE3023396C2 (en) Medicines for intravenous cancer therapy
Deacock et al. The influence of certain ganglionic blocking agents on neuromuscular transmission
DE3880498T2 (en) USE OF 5-AMINOSALICYL ACID (5-ASA) FOR PRODUCING A MEDICINAL PREPARATION FOR USE IN A REPERFUSION TREATMENT.
EP0788355B1 (en) Use of intravenously administered iron in the therapy of tumoral and infectious diseases
DE2508338A1 (en) MEDICINAL PRODUCTS FOR CANCER CONTROL
Dann The effects of different levels of ventilation on the action of pancuronium in man

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee